Intra- and intercellular signaling pathways associated with drug-induced cardiac pathophysiology

Area of Science:

• Cardiovascular Biology
• Oncology
• Systems Biology

Background:

• Cardiac function relies on complex intra- and intercellular signaling pathways involving multiple cell types.
• Oncology therapies can perturb these critical cardiac signaling pathways.
• Increased cancer survival rates highlight the growing prevalence of cancer treatment-related cardiovascular complications, including heart failure.

Purpose of the Study:

• To discuss how homotypic and heterotypic cellular interactions form the basis of cardiac signaling.
• To explain the mechanisms by which oncological agents disrupt these pathways, leading to cardiotoxicity and heart failure.
• To highlight the utility of systems biology approaches in understanding cardiovascular toxicity.

Main Methods:

• Review and discussion of established knowledge on cardiac cell-cell interactions and signaling.
• Analysis of known effects of oncological agents on cardiac physiology.
• Exploration of emerging systems biology techniques for studying complex biological systems.

Main Results:

• Oncological agents disrupt both intra- and intercellular cardiac signaling pathways.
• These disruptions compromise cardiac function, potentially leading to heart failure.
• Cellular interactions, both within the same cell type (homotypic) and between different cell types (heterotypic), are fundamental to cardiac homeostasis and susceptible to disruption.

Conclusions:

• Understanding the disruption of cardiac signaling pathways by cancer therapies is essential for managing cardiotoxicity.
• Systems biology offers powerful tools to investigate the multifaceted cellular signaling involved in cardiovascular complications of cancer treatment.
• Further research into these pathways can lead to strategies for preventing or mitigating cancer therapy-induced heart failure.